MEETING AGENDA

Future Concepts for Disruptive Therapeutics

April 24 to 27, 2022
The Banbury Center, Lloyd Harbor, New York

This meeting was funded by
Ionis Pharmaceuticals

Organizers:
David Ecker, Ionis Pharmaceuticals, and
Michael Hayden, University of British Columbia

In recent decades, new technologies, coupled with a much deeper understanding of the biology of disease processes, have led to breakthroughs in therapy. This meeting convened diverse experts and stakeholders to present new therapeutic concepts and discussed what needs to happen to enable the vision in an innovative and equitable way. Core themes, including new technologies, landscapes, and integration in a world of silos, provided the backbone for these discussions.

SUNDAY, APRIL 24

Afternoon
6:00 pm Arrivals and check-in
Reception and dinner

MONDAY, APRIL 25

7:15 am Breakfast

8:30 am Welcome, Introduction, Meeting Objectives
Rebecca Leshan, Banbury Center
David Ecker, Ionis Pharmaceuticals
9:00 am  SESSION 1: Emerging Landscapes  
Christopher Lowe, University of Cambridge  
Banning Garrett, Singularity University  
[virtual] Joe Arron, 23andMe  
Michael Hayden, University of British Columbia  
Joni Rutter, National Center for Advancing Translational Sciences, NIH

12:00 pm  Luncheon

1:30 pm  (continued) SESSION 1: Emerging Landscapes  
Xuanhe Zhao, Massachusetts Institute of Technology  
Timothy Broderick, Institute for Human and Machine Cognition

2:30 pm  SESSION 2A: Emerging Platforms I  
Xandra Breakefield, Massachusetts General Hospital & Harvard Medical School  
Alfica Sehgal, CAMP4 Therapeutics  
Chrystal Louis, CRISPR Therapeutics  
Janice Chen, Mammoth Biosciences

4:50 pm  General Discussion & End of Day Wrap-up

6:00 pm  Reception and dinner

TUESDAY, APRIL 26

7:15 am  Breakfast

8:30 am  SESSION 2B: Emerging Platforms II  
Frank Bennett, Ionis Pharmaceuticals  
Adrian Krainer, Cold Spring Harbor Laboratory  
Barry Canton, Ginkgo Bioworks  
Kevin Tracey, The Feinstein Institutes for Medical Research  
Simone Fishburn, BioCentury Inc.

11:30 am  General Discussion

12:00 pm  Luncheon
SESSION 3: Trends
Clarice Aiello, University of California, Los Angeles
Sidney Hecht, Arizona State University
Amy Bernard, Kavli Foundation
Tobias Janowitz, Cold Spring Harbor Laboratory

3:45 pm SESSION 4: Legal and Ethical Considerations
Shawneequa Callier, George Washington University
Thomas Wilson Williams, Duke University

4:45 pm General Discussion & End of Day Wrap-Up
6:00 pm Reception and dinner

WEDNESDAY, APRIL 27

7:15 am Breakfast

8:30 am SESSION 5: Global Equity
Yesim Tozan, New York University
Dan Wattendorf, Bill & Melinda Gates Foundation

9:00 am Group Discussion

10:15 am SESSION 6: Meeting Wrap-Up & Next Steps
Moderated Group Discussion

12:15 pm Luncheon
2:00 pm Participant departures

— END OF PROGRAM —
PARTICIPANTS LIST

Clarice Aiello, University of California, Los Angeles
Joseph Arron, 23andMe
Frank Bennett, Ionis Pharmaceuticals
Amy Bernard, Kavli Foundation
Xandra Breakefield, Massachusetts General Hospital & Harvard Medical School
Timothy Broderick, Institute for Human and Machine Cognition
Shawneequa Callier, George Washington University
Barry Canton, Ginkgo Bioworks
Janice Chen, Mammoth Biosciences
David Ecker, Ionis Pharmaceuticals
Simone Fishburn, BioCentury Inc.
Banning Garrett, Singularity University
Ryan Hammer, KnowInnovation
Michael Hayden, University of British Columbia
Sidney Hecht, Arizona State University
Tobias Janowitz, Cold Spring Harbor Laboratory
Adrian Krainer, Cold Spring Harbor Laboratory
Chrystal Louis, CRISPR Therapeutics
Christopher Lowe, University of Cambridge
Joni Rutter, National Center for Advancing Translational Sciences, NIH
Alfica Sehgal, CAMP4 Therapeutics
Yesim Tozan, New York University School of Global Public Health
Kevin Tracey, The Feinstein Institutes for Medical Research
Daniel Wattendorf, Bill & Melinda Gates Foundation
Thomas Wilson Williams, Duke Initiative for Science & Society
Xuanhe Zhao, Massachusetts Institute of Technology